KFS
CTXR icon

Keynote Financial Services’s Citius Pharmaceuticals CTXR Stock Holding History

Keynote Financial Services’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-700
Closed -$8.76K – 153
2024
Q3 		$8.76K Hold
700
– – 0.01% 155
2024
Q2 		$10.2K Hold
700
– – 0.01% 149
2024
Q1 		$15.7K Buy
+700
New +$12.8K 0.01% 150

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Keynote Financial Services's CTXR Position: Q4 2024 in Review

Keynote Financial Services sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 700 shares — an estimated $8.76K sold.

Keynote Financial Services first reported a position in CTXR in Q1 2024 and held it in 3 quarters. The position peaked at $15.7K in Q1 2024. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Keynote Financial Services reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Keynote Financial Services sold 700 Citius Pharmaceuticals shares in Q4 2024, an estimated $8.76K.
  • Keynote Financial Services first reported a position in Citius Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Keynote Financial Services's Citius Pharmaceuticals position peaked at $15.7K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Keynote Financial Services's 13F filing for Q4 2024, filed 5 Feb 2025.